TALPHERA, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Talphera's NEPHRO CRRT Phase 3 clinical study for nafamostat is 75% enrolled (expected completion by year-end 2026). The 2026 KDIGO Clinical Practice Guidelines added nafamostat as an acceptable regional anticoagulant for continuous renal replacement therapy—a positive regulatory signal versus prior guidance. Updated market research estimates ~200,000 annual U.S. CRRT procedures in 2027, up 21% from prior estimates. As of June 30, 2026, Talphera held $17.1M in cash and investments; Q2 2026 net loss was $4.3M ($0.06 per share) on $3.9M combined R&D and SG&A expenses.
Why this rating
Study enrollment progress + regulatory guideline endorsement are material for a $8.3M-cap biotech. 75% trial completion within target timeline and KDIGO backing materially improve approval/commercialization odds; $17.1M cash (2× market cap) funds near-term milestones but burn is steep.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.